Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial

Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value for the Primary Completion Date (Estimated) has recently changed. This change may indicate a shift in the expected completion timeline for the clinical trial related to the study on Ado-Trastuzumab Emtansine for patients with HER2 amplified or mutant cancers.
    Difference
    0.1%
    Check dated 2024-05-10T08:13:22.000Z thumbnail image
  7. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 2023-06-15 to 2024-05-08, indicating an update in the estimated primary completion date of the clinical trial involving the drug ado-trastuzumab emtansine for patients with HER2 amplified or mutant cancers. This change suggests a potential shift in the timeline for the study's completion and results availability in the medical and healthcare-related publications and documentation.
    Difference
    2%
    Check dated 2024-05-09T01:47:09.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:44:25.000Z thumbnail image

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.